Solstice Biologics, a San Diego-based biotech startup focused on solving the problem of targeting and delivering nucleic acid therapeutics, has raised $18m in Series A financing.
The round was led by venBio, with participation from Aeris Capital AG.
Founded by Steven Dowdy, Ph.D., professor of Cellular and Molecular Medicine at UC San Diego, and Curt Bradshaw, Ph.D. (Chief Scientific Officer), who heads its research laboratories in San Diego, CA, Solstice is developing proprietary technology that enables short double-stranded RNAi and microRNA molecules to cross cell membranes. The company has also acquired an exclusive license to University of California, San Diego intellectual property covering technology that enables RNA molecules to cross membranes of multiple cell types.
Dowdy and Bradshaw joined Corey Goodman, Ph.D., Executive Chairman of Solstice Biologics (and a Managing Director of venBio), Rob Adelman, M.D. (venBio) and Frank Muehlenbeck, Ph.D. (Aeris), on the company’s Board of Directors.